Literature DB >> 8054502

Reduced oxygenation in a rat mammary carcinoma post-radiation and reoxygenation with a perflubron emulsion/carbogen breathing.

B A Teicher1, N P Dupuis, M F Robinson, T Kusumoto, M Liu, K Menon.   

Abstract

Oxygen profiles of the rat mammary 13672 carcinoma were determined using a pO2 histograph prior to treatment and 24 hrs. and 48 hrs. after 2 or 5 fractions of 3 gray given once daily. The tumors were much more hypoxic at 24 hrs. post radiation therapy than prior to therapy. There was little increase in the oxygenation of the tumors at 48 hrs. post therapy compared with 24 hrs. post therapy indicating that reoxygenation was occurring very slowly in this tumor. Carbogen breathing improved the oxygenation of the tumors under each of the conditions studied. Administration of a perflubron emulsion (8 ml/kg) produced little or no change in the oxygenation of the tumors under normal air breathing conditions. However, with the addition of carbogen breathing to administration of the perflubron emulsion there was an increase in the mean/median pO2's of the tumors to levels equal to or greater than carbogen breathing alone. Perhaps most significantly administration of the perflubron emulsion with carbogen breathing increased the oxygenation of the most hypoxic regions of the tumors but carbogen breathing alone did not.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8054502

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  5 in total

Review 1.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

2.  Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells.

Authors:  G-One Ahn; J Martin Brown
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

3.  Expression of DDX3 is directly modulated by hypoxia inducible factor-1 alpha in breast epithelial cells.

Authors:  Mahendran Botlagunta; Balaji Krishnamachary; Farhad Vesuna; Paul T Winnard; Guus M Bol; Arvind H Patel; Venu Raman
Journal:  PLoS One       Date:  2011-03-23       Impact factor: 3.240

4.  In vitro anti-cancer activity of doxorubicin against human RNA helicase, DDX3.

Authors:  Mahendran Botlagunta; Bhulakshmi Kollapalli; Lavanya Kakarla; Siva Priya Gajarla; Sai Pujitha Gade; Chandra Lekha Dadi; Akhila Penumadu; Shaik Javeed
Journal:  Bioinformation       Date:  2016-10-18

5.  Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.

Authors:  Sabindra K Samal; Samapika Routray; Ganesh Kumar Veeramachaneni; Rupesh Dash; Mahendran Botlagunta
Journal:  Sci Rep       Date:  2015-04-28       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.